- Charles River reported Q4 2018 results that beat the top- and bottom-line estimates.
- This small-cap drug discovery and early-stage development company has a great long-term story to tell. Additionally, I believe that the company's investment thesis keeps getting stronger.
- I am long Charles River, and I am looking to add to my position in 2019.
Charles River Laboratories ($CRL) has been one of the best-performing stocks in the R.I.P. portfolio. CRL's shares are up 24% on a YTD basis, and the stock is outperforming the S&P 500 (SPY) by almost 25 percentage points over the last 12 months.
Investors may be asking themselves if they missed the boat, but I would contend that the story is just getting started. As such, I believe that Charles River is a great, long-term buy at today's price, because, as I recently described, this drug discovery and early-stage development company is well-positioned for the future. And the company's most recent results prove it.
Read more here.